Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy-Reference-Cited by-全球学者库

Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Published:2021-10-21 Issue:1 Volume:49 Page:61-81
ISSN:0303-6987
Container-title:Journal of Cutaneous Pathology
language:en
Short-container-title:J Cutan Pathol

Author:

Seervai Riyad N. H.¹²³^ORCID,Cho Woo Cheal⁴^ORCID,Chu Emily Y.⁵^ORCID,Marques‐Piubelli Mario L.⁶^ORCID,Ledesma Debora A.⁶^ORCID,Richards Kristen⁷^ORCID,Heberton Meghan M.⁷^ORCID,Nelson Kelly C.⁷^ORCID,Nagarajan Priyadharsini⁴^ORCID,Torres‐Cabala Carlos A.⁴⁷^ORCID,Prieto Victor G.⁴⁷^ORCID,Curry Jonathan L.⁴⁶^ORCID

Affiliation:

1. Medical Scientist Training Program Baylor College of Medicine Houston Texas USA

2. Department of Molecular and Cellular Biology Baylor College of Medicine Houston Texas USA

3. Department of Dermatology Baylor College of Medicine Houston Texas USA

4. Department of Pathology, Section of Dermatopathology The University of Texas MD Anderson Cancer Center Houston Texas USA

5. Department of Dermatology The University of Pennsylvania Philadelphia Pennsylvania USA

6. Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston Texas USA

7. Department of Dermatology The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Dermatology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cup.14145

Reference335 articles.

1. The Hallmarks of Cancer

2. Hallmarks of Cancer: The Next Generation

3. Small molecules, big impact: 20 years of targeted therapy in oncology

4. Cutaneous Adverse Reactions of Anticancer Agents

5. Cutaneous manifestations of nontargeted and targeted chemotherapies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case series;JAAD Case Reports;2024-01

2. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10

3. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune‐related adverse event reveal upregulation of toll‐like receptor 4/complement‐induced innate immune response and increased density of T_H1 T‐cells;Journal of Cutaneous Pathology;2023-05-07

4. The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy;Journal of Cutaneous Pathology;2022-10-03

5. Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor;Cureus;2022-03-18